Intra-Cellular Therapies, Inc.: insider trades · United States · SEC (Form 4)

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. is a US-based biopharmaceutical company listed on NASDAQ in the United States and focused on central nervous system disorders, with a specialty in discovering, developing, and commercializing innovative psychiatric therapies. The company is headquartered in Bedminster, New Jersey. Its scientific roots are tied to intracellular signaling research, and its commercial identity is now anchored by its lead asset, CAPLYTA® (lumateperone). ([intracellulartherapies.com](https://www.intracellulartherapies.com/Contact-us/?utm_source=openai)) The company’s business model is currently driven by CAPLYTA, an atypical antipsychotic approved in the US for schizophrenia in adults and for bipolar depression in adults. In addition, Intra-Cellular Therapies has pursued a supplemental filing for adjunctive treatment of major depressive disorder, which could significantly broaden the product’s addressable market if approved. Its 2024 results showed strong commercial momentum, with CAPLYTA net product sales rising materially year over year, underscoring improving market penetration and effective execution in a highly specialized therapeutic area. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai)) From a competitive standpoint, the company occupies an attractive but highly competitive niche in specialty psychiatry. Its differentiation comes from a clinically established lead product and a pipeline that includes non-lumateperone programs such as ITI-1284, ITI-214, and ITI-1500. This gives the business both near-term commercial leverage and longer-term pipeline optionality. In neuropsychiatry, where tolerability, efficacy, and prescriber familiarity matter greatly, a differentiated profile can be a meaningful advantage, but sustained growth still depends on label expansion, physician adoption, and payer access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai)) Recent milestones have been important for the investment case. The FDA accepted the company’s supplemental NDA for CAPLYTA in adjunctive MDD, while 2024 sales growth confirmed the product’s commercial trajectory. The company also expanded its sales effort to support a potential broader launch. A major corporate development is that Johnson & Johnson completed its acquisition of Intra-Cellular Therapies on April 2, 2025, which materially changes the ownership and strategic context of the asset. For investors, the key questions are now centered on CAPLYTA’s continued franchise expansion, the regulatory path for additional indications, and how the neuropsychiatric platform is ultimately integrated within a global pharmaceutical portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai))